(Q42872330)

9 November 2017

Alzheimer's failure raises questions about disease-modifying strategies (English)

1 reference

9 November 2017

0 references

1

Andy Extance

0 references

author name string

Andy Extance

series ordinal

1

1 reference

9 November 2017

1 October 2010

1 reference

Nature Reviews Drug Discovery

9 November 2017

1 reference

9 November 2017

9

1 reference

9 November 2017

749-751

1 reference

9 November 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3288

9 November 2017

0 references

cites work

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

1 reference

Mixed results for disease-modification strategies for Alzheimer's disease.

31 March 2020

1 reference

Hope builds for earlier detection of Alzheimer's disease.

31 March 2020

1 reference

Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease

31 March 2020

1 reference

Gleevec inhibits β-amyloid production but not Notch cleavage

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD3288

1 reference

9 November 2017

1 reference

PubMed ID

20885394